Physician profile
Evan B Krisch
NPI 1588621189
$651.80
in general payments reported to CMS, 2019-2025
16 companies · $32.40 in 2025
The $32.40 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $175 · 2021: $152 · 2022: $65.00 · 2025: $32.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $32.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $32.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $344.07 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.49 | 2019-2020 | |
| Myovant Sciences INC. | $37.79 | 2021 | |
| Abbvie INC. | $31.20 | 2019-2025 | |
| Pfizer INC. | $30.20 | 2020 | |
| Amgen INC. | $24.55 | 2021 | |
| Mission Pharmacal Company | $17.48 | 2021 | |
| Antares Pharma, INC. | $17.28 | 2021 | |
| Boston Scientific Corporation | $16.35 | 2020 | |
| Merck Sharp & Dohme LLC | $14.93 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $14.00 | 2025 | Bard Urinary Drainage Bag |
| Astrazeneca Pharmaceuticals LP | $13.91 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.60 | 2020 | |
| Metuchen Pharmaceuticals | $13.48 | 2020 | |
| Clarus Therapeutics INC. | $13.28 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $11.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Krisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.